Development of Celiac Disease Therapeutics: Report of the Third Gastroenterology Regulatory Endpoints and Advancement of Therapeutics Workshop

被引：21
作者：
Leffler, Daniel [1 ]
Kupfer, Sonia S. [2 ]
Lebwohl, Benjamin [3 ]
Bugin, Kevin [4 ]
Griebel, Donna [4 ]
Lathrop, Julia Tait [4 ]
Lee, Jessica J. [4 ]
Mulberg, Andrew E. [4 ]
Papadopoulos, Elektra [4 ]
Tomaino, Juli [4 ]
Crowe, Sheila E. [5 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Columbia Univ, Dept Med, New York, NY USA
[4] US FDA, Silver Spring, MD USA
[5] Univ Calif San Diego, Dept Med, 9500 Gilman Dr,BRF 2,Off 4A30, La Jolla, CA 92093 USA
来源：
GASTROENTEROLOGY | 2016年 / 151卷 / 03期
关键词：
GLUTEN-FREE DIET; PREDICTORS; ANTIBODIES; DIAGNOSIS; MORTALITY; SYMPTOMS; ADULTS;
D O I：
10.1053/j.gastro.2016.07.025
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：407 / 411
页数：5
相关论文
共 8 条
  • [1] Novel Drug Therapeutics in Celiac Disease: A Pipeline Review
    Varma, Sanskriti
    Krishnareddy, Suneeta
    DRUGS, 2022, 82 (15) : 1515 - 1526
  • [2] Celiac Disease and Drug Absorption: Implications for Cardiovascular Therapeutics
    Wang, Ian
    Hopper, Ingrid
    CARDIOVASCULAR THERAPEUTICS, 2014, 32 (06) : 253 - 256
  • [3] Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials
    Gottlieb, Klaus
    Dawson, Jill
    Hussain, Fez
    Murray, Joseph A.
    GASTROENTEROLOGY REPORT, 2015, 3 (02): : 91 - 102
  • [4] Therapeutics Development for Cystic Fibrosis: A Successful Model for a Multisystem Genetic Disease
    Ashlock, Melissa A.
    Olson, Eric R.
    ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 : 107 - 125
  • [5] Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies - A stakeholder meeting report
    Meln, Irina
    Cnossen, Victor
    Corti, Nicoletta
    Andeweg, Arno
    Baay, Marc
    Chiu, Christopher
    Coia, John
    Cornely, Oliver
    Cox, Rebecca J.
    Dasyam, Dileep
    Keersmaecker, Sigrid C. J. De
    Deming, Meagan
    Waldock, Joanna
    Engelhardt, Othmar G.
    Guo, Manman
    Saflo, Okba Haj-Ali
    Hensen, Annefleur
    Jeeninga, Rienk
    Kolstoe, Simon
    Krut, Oleg
    Kuijper, Ed J.
    Leal, Lorna
    Mazur, Natalie
    Mohn, Kristin G. I.
    Morel, Sandra
    Osterhaus, Ab
    Moreira, Augustin Portela
    Smits, Wiep Klaas
    Sridhar, Saranya
    Toomey, Danny
    van Gerven, Joop
    Vehreschild, Maria J. G. T.
    Yarzabal, Juan Pablo
    Zimmer-Harwood, Paul
    Neels, Pieter
    Olesen, Ole F.
    Roestenberg, Meta
    Kamerling, Ingrid M. C.
    BIOLOGICALS, 2025, 90
  • [6] The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease
    Bai, Xiaoxue
    Zhu, Jiawei
    Chen, Yao
    Sun, Haopeng
    FUTURE MEDICINAL CHEMISTRY, 2025, 17 (02) : 221 - 236
  • [7] Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
    Do, Albert
    Ilagan-Ying, Ysabel C.
    Mehal, Wajahat Z.
    Lim, Joseph K.
    EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (02) : 125 - 134
  • [8] Development and Validation of the Celiac Disease-Children's Activities Report (CD-Chart) for Promoting Self-Management among Children and Adolescents
    Meyer, Sonya
    Rosenblum, Sara
    NUTRIENTS, 2017, 9 (10)
1